Extraordinary general meeting of Nuevolution AB (publ)

An extraordinary general meeting in Nuevolution AB (publ) was held on 1 July 2016.

The extraordinary general meeting resolved to amend the terms and conditions of the company’s incentive program, warrant program 2015/2021, in accordance with the major shareholders’ proposal. The complete proposal is included in the notice for the general meeting available on the company’s website. The resolution entails an amendment of the terms and conditions of warrants of Series 1 and Series 2.

It was, inter alia, resolved to amend the terms and conditions for warrants of Series 1 and Series 2 so that applicable so-called “exit events” also shall include a listing on Nasdaq First North. In addition, in order for the applicable exit event relating to warrants of Series 1 to occur, the value per share, at the time of application for subscription of shares by exercise of warrants, shall correspond to at least SEK 22.975. Upon fulfillment of an exit event relating to Series 1, the subscription price per share shall be lowered to SEK 17.50, and for Series 2, the subscription price per share shall be lowered to SEK 11.25. As a result of the general meeting’s resolution to amend the terms and conditions of the warrants, exit event relating to warrants of Series 2 has been fulfilled.

For more information, please contact:

Alex Haahr Gouliaev, CEO

Phone: +45 7020 0987

Email: ahg@nuevolution.com

Henrik D. Simonsen, CFO

Phone: +45 3913 0947

Email: hs@nuevolution.com

About Nuevolution

Nuevolution AB (publ) is a leading small molecule drug discovery biotech company founded in 2001, headquartered in Copenhagen, Denmark. Nuevolution partners its proprietary discovery platform and programs with pharmaceutical and biotechnology companies to seek future benefit of patients in need of novel medical treatment options. Nuevolution’s internal programs are focused on therapeutically important targets within inflammation, oncology and immuno-oncology.

Nuevolution AB (publ) is required to disclose the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was sent for publication on Friday 1 July 2016, 13:00 (CET).

Nuevolution AB (publ) is listed at Nasdaq First North Premier in Stockholm, Sweden (ticker: NUE). Västra Hamnen Corporate Finance AB acts as Certified Adviser to Nuevolution AB (publ). More information about Nuevolution can be found on: www.nuevolution.com

Tags:

EGM

About Us

Nuevolution is a biotechnology company with a unique business model, where continuous revenue generation and risk mitigation represent primary objectives. This strategy is executed by a “multiple shots at goal” approach in combination with reduced research costs, where simultaneous development of multiple programs in parallel is made possible. Nuevolution is the inventor of Chemetics®. Chemetics® is a patent protected drug discovery research platform, which enables identification of small molecule (tablet based) drug candidates much more effectively and at lower cost than what is possible by other conventional methods. Nuevolution applies its research platform for the identification and development of its own pipeline of drug candidates for treatment of cancer and chronic inflammatory diseases Nuevolution applies a business model that is unique for a biotechnology company with a primary focus on revenue generation and risk minimization (i.e. lower cost development) by having a number of programs developed in parallel. Nuevolution is the inventor of Chemetics® , a patent protected drug discovery platform which enables efficient discovery of novel chemical small molecule leads for specific indications addressing disease targets within the company’s therapeutic focus areas

Subscribe

Documents & Links